Table 5 Univariate and multivariate Cox regression analysis of CSS in patients with renal cell carcinoma and tumor thrombus after radical nephrectomy and thrombectomy

Gender (female vs. male)

0.327

0.076–1.405

Age

0.995

0.955–1.036

Body mass index

0.974

0.867–1.093

 I

–

–

 II

0.942

0.123–7.189

 III

1.996

0.238–16.772

Side (right vs. left)

0.762

0.325–1.786

Tumor diameter

1.088

0.978–1.210

Tumor thrombus grade

 0

–

–

 I

0.474

0.138–1.621

 II

0.706

0.222–2.248

 III

1.172

0.342–4.012

 IV

0.732

0.152–3.527

Preoperative serum creatinine

0.999

0.991–1.008

Preoperative eGFR

1

0.979–1.020

Operation approach (open vs. laparoscopy)

2.085

0.890–4.884

Ipsilateral adrenalectomy (present vs. absent)

2.087

0.846–5.149

Lymph node dissection (present vs. absent)

3.008

1.109–8.162

Operation time

1.002

0.999–1.005

Pathological type (non-clear cell carcinoma vs. clear cell carcinoma)

1.996

0.767–5.037

WHO/ISUP 2016 Nuclear classification(12vs.34)

3.843

1.135–13.012

 T3a

 T3b

 T3c

 T4

Lymph node metastasis (present vs. absent)

4.166

1.522–11.402

Metastasis (present vs. absent)

2.04

0.870–4.782

Vascular wall invasion (present vs. absent)

1.18

0.471–2.952

Lymphatic vascular invasion (present vs. absent)

2.305

0.996–5.334

Perinephric tissues invasion (present vs. absent)

4.029

1.709–9.497

Renal pelvis invasion (present vs. absent)

1.876

0.679–5.180

Necrosis (present vs. absent)

1.704

0.729–3.981

Sarcomatoid differentiation (present vs. absent)

3.417

1.431–8.160

Postoperative complications (present vs. absent)

2.499

1.016–6.146

ACE (> 13.9 vs. ≤13.9)

3.274

1.331–8.052

PCE (> 0.16 vs. ≤0.16)

2.322

0.982–5.494